PAG
RARE icon

Private Advisor Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Private Advisor Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,100
Closed -$291K – 1957
2020
Q4 		$291K Buy
+2,100
New +$249K ﹤0.01% 1475
2020
Q3 		– Sell
-600
Closed -$47K – 2998
2020
Q2 		$47K Buy
+600
New +$39.7K ﹤0.01% 2134

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Private Advisor Group's RARE Position: Q1 2021 in Review

Private Advisor Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 2,100 shares — an estimated $291K sold.

Private Advisor Group first reported a position in RARE in Q2 2020 and held it in 2 quarters. The position peaked at $291K in Q4 2020. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

  • Private Advisor Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Private Advisor Group sold 2,100 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $291K.
  • Private Advisor Group first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 2 quarters.
  • Private Advisor Group's Ultragenyx Pharmaceutical position peaked at $291K in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Private Advisor Group's 13F filing for Q1 2021, filed 22 Apr 2021.